{"id":3202,"count":31,"description":"Hiperplazia benign\u0103 de prostat\u0103 (HBP) este o m\u0103rire non-canceroas\u0103 a prostatei care afecteaz\u0103 p\u00e2n\u0103 la 50% dintre b\u0103rba\u021bii peste 60 de ani \u0219i 80% dintre b\u0103rba\u021bii peste 80 de ani. Simptomele includ jet slab, ezitare, intermiten\u021b\u0103, nicturie \u0219i golire incomplet\u0103 \u2014 denumite colectiv simptome ale tractului urinar inferior (STUI). Managementul medical modern utilizeaz\u0103 trei clase de medicamente, singure sau \u00een combina\u021bie, cu ad\u0103ugarea de tadalafil 5 mg zilnic pentru b\u0103rba\u021bii cu at\u00e2t HBP, c\u00e2t \u0219i disfunc\u021bie erectil\u0103. Toate produsele MedsBase pentru HBP sunt furnizate de <strong>produc\u0103tori certifica\u021bi WHO-GMP<\/strong>.\n\n<strong>Alfa-blocante \u2014 tratament de prim\u0103 linie pentru ameliorarea simptomelor.<\/strong> Antagoni\u0219tii selectivi alfa-1 relaxeaz\u0103 mu\u0219chiul neted din prostat\u0103, g\u00e2tul vezicii \u0219i uretr\u0103 pentru a \u00eembun\u0103t\u0103\u021bi fluxul \u0219i a reduce simptomele obstructive \u00een 1\u20132 s\u0103pt\u0103m\u00e2ni. Nu reduc volumul prostatei sau nu modific\u0103 evolu\u021bia pe termen lung \u2014 doar amelior\u00e2nd simptomele. Tamsulosin 0.4 mg (cel mai selectiv pentru prostat\u0103, cu cele mai pu\u021bine efecte secundare legate de tensiune) este disponibil sub form\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/urimax\/\">Urimax<\/a>, <a href=\"https:\/\/medsbase.com\/ro\/urimax-capsule\/\">Urimax Capsule<\/a>, <a href=\"https:\/\/medsbase.com\/ro\/tamsuheal\/\">Tamsuheal<\/a>, , <a href=\"https:\/\/medsbase.com\/ro\/urimax-d\/\">Urimax-D<\/a> (cu dutasterid\u0103) \u0219i <a href=\"https:\/\/medsbase.com\/ro\/urimax-f\/\">Urimax-F<\/a> (cu finasterid\u0103). Alfuzosin cu eliberare prelungit\u0103 10 mg sub form\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/monolosin\/\">Monolosin<\/a>. . <a href=\"https:\/\/medsbase.com\/ro\/temsunol\/\">Silodosin 8 mg (cel mai uroselectiv, cu cele mai pu\u021bine efecte asupra tensiunii, dar cu cea mai mare rat\u0103 de ejaculare retrograd\u0103) sub form\u0103 de<\/a>, <a href=\"https:\/\/medsbase.com\/ro\/temsunol-capsule\/\">Temsunol<\/a>, Temsunol Capsule <a href=\"https:\/\/medsbase.com\/ro\/temsunol-f\/\">, \u0219i combina\u021bii<\/a> \u0219i <a href=\"https:\/\/medsbase.com\/ro\/temsunol-d\/\">Temsunol-F<\/a>. Temsunol-D.\n\n<strong>. Efecte secundare comune clasei: ame\u021beli la sculare (mai ales dup\u0103 prima doz\u0103), ejaculare retrograd\u0103, congestie nazal\u0103. Important: avertiza\u021bi anestezistul \u00eenainte de opera\u021bia de cataract\u0103 (sindromul irisului flasc intraoperator).<\/strong> Finasteride 5 mg \u0219i dutasteride 0,5 mg blocheaz\u0103 conversia testosteronului \u00een dihidrotestosteron, reduc\u00e2nd volumul prostatei cu ~20\u201325% \u00een 6\u201312 luni. Acestea reduc riscul de reten\u021bie urinar\u0103 acut\u0103 \u0219i necesitatea de interven\u021bie chirurgical\u0103. Alinarea simptomelor este mai lent\u0103 dec\u00e2t la blocatele alfa (3\u20136 luni), dar ac\u021bioneaz\u0103 asupra cauzei subiacente. Finasteride 5 mg (primul 5-ARI de la MERCK) este disponibil sub form\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/proscar\/\">Proscar<\/a> \u0219i <a href=\"https:\/\/medsbase.com\/ro\/proscalpin\/\">Proscalpin<\/a>. Dutasteride 0,5 mg ca <a href=\"https:\/\/medsbase.com\/ro\/dutanol\/\">Dutanol<\/a> \u0219i combina\u021bia <a href=\"https:\/\/medsbase.com\/ro\/dutas-t\/\">Dutas T<\/a> (cu tamsulosin). Formul\u0103rile de Finasteride 1 mg sunt listate \u00een sec\u021biunea noastr\u0103 <a href=\"https:\/\/medsbase.com\/ro\/hair-loss-treatment-for-men\/\">Tratament pentru Pierderea P\u0103rului la B\u0103rba\u021bi<\/a> \u2014 aceea\u0219i molecul\u0103, doz\u0103 diferit\u0103. Efecte secundare: libido sc\u0103zut (~3\u20135%), disfunc\u021bie erectil\u0103 (~3\u20135%), volum seminal redus, ginecomastie (rar). Unii b\u0103rba\u021bi raporteaz\u0103 sindrom post-finasteride persistent \u2014 discuta\u021bi riscurile \u00eenainte de \u00eenceperea tratamentului.\n\n<strong>Inhibitori PDE-5 pentru BPH + ED combinat.<\/strong> Tadalafil 5 mg o dat\u0103 pe zi este aprobat de FDA pentru simptomele urinare de tip BPH (singur sau \u00een combina\u021bie cu blocator alfa). \u00cembun\u0103t\u0103\u021be\u0219te at\u00e2t simptomele urinare, c\u00e2t \u0219i func\u021bia erectil\u0103 la b\u0103rba\u021bii cu ambele afec\u021biuni \u2014 o solu\u021bie unic\u0103 pentru dou\u0103 probleme. Stoc\u0103m tadalafil \u00een doze mici sub multiple m\u0103rci listate \u00een <a href=\"https:\/\/medsbase.com\/ro\/tadalafil\/\">Tadalafil<\/a> catalogul nostru, precum \u0219i combina\u021bii precum <a href=\"https:\/\/medsbase.com\/ro\/tadalista\/\">Tadalista<\/a> \u0219i <a href=\"https:\/\/medsbase.com\/ro\/vidalista\/\">Vidalista<\/a>. Tadalafil \u00een doze mai mari \u0219i al\u021bi inhibitori PDE-5 se g\u0103sesc \u00een sec\u021biunea noastr\u0103 mai larg\u0103 <a href=\"https:\/\/medsbase.com\/ro\/erectile-dysfunction\/\">Medicamente pentru disfunc\u021bie erectil\u0103<\/a> catalog.\n\n<strong>Cum s\u0103 alegi.<\/strong> Simptome u\u0219oare (IPSS  30 mL sau PSA &gt; 1,4 ng\/mL (markeri de risc pentru progresie). Simptome severe (IPSS &gt; 19) sau reten\u021bie recurent\u0103 \u2192 combina\u021bie alpha-blocant + 5-ARI \u00b1 trimitere la op\u021biuni chirurgicale (TURP, HoLEP, PVP, ridicarea uretral\u0103 prostatic\u0103, abla\u021bie cu abur de ap\u0103). ED concomitent \u2192 lua\u021bi \u00een considerare tadalafil 5 mg zilnic ca monoterapie sau combina\u021bie.\n\n<strong>Important.<\/strong> Acute urinary retention (sudden complete inability to void with painful bladder distension) is a urological emergency \u2014 go to A&amp;E. New haematuria, perineal pain, weight loss, or PSA rise above expected age range warrants prompt urology referral to exclude prostate cancer. PSA testing is a separate decision discussed with your GP \u2014 BPH treatment with 5-ARIs lowers PSA by ~50%, factor this into surveillance interpretation. Avoid alpha-blockers in patients on PDE-5 inhibitors at full doses without dose review (additive hypotension risk).\n\nAll MedsBase BPH products ship from <strong>produc\u0103tori certifica\u021bi WHO-GMP<\/strong> cu ambalaj discret \u0219i sunt acoperite de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>.","link":"https:\/\/medsbase.com\/ro\/benign-prostatic-hyperplasia-bph-treatment\/","name":"Tratamentul Hiperplaziei Benigne de Prostat\u0103 (BPH)","slug":"benign-prostatic-hyperplasia-bph-treatment","taxonomy":"product_cat","parent":3142,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3142"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product?product_cat=3202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}